### Table S1 Socio-demographic and clinical characteristics of enrolled children, n= 3140

|                                | n (%)          |
|--------------------------------|----------------|
| **Age**                        |                |
| Mean (SD) in months            | 10.5 (6.0)     |
| 0–3 months                     | 304 (9.7)      |
| 4–11 months                    | 1604 (51.1)    |
| 12-23 months                   | 1232 (39.2)    |
| **Gender**                     |                |
| Male                           | 1580 (50.3)    |
| **Hospital Admissions in last year** |            |
| None                           | 3046 (97.0)    |
| One                            | 83 (2.6)       |
| Greater than or equal to two   | 11 (0.4)       |
| **Outpatient visits in last month** |          |
| None                           | 1611 (51.3)    |
| One                            | 797 (25.4)     |
| Two                            | 465 (14.8)     |
| Greater than 2                 | 267 (8.5)      |
| **Smoker in household**        |                |
| Yes                            | 1116 (35.5)    |
| **Symptoms during last two weeks** |              |
| Runny nose                     | 1584 (51.6)    |
| Cough                          | 1220 (39.8)    |
| Fever                          | 1463 (47.7)    |
| Fast breathing                 | 79 (2.6)       |
| Difficulty in breathing        | 612 (19.9)     |
| Lower chest indrawing          | 74 (2.4)       |
| **Signs**                      |                |
| Hypothermia <35⁰C              | 11 (0.4)       |
| Hyperthermia >37.5             | 187 (6.1)      |
| Tachypnea***                  | 210 (6.9)      |
| Lower chest indrawing          | 47 (1.5)       |
| **Number of PCV10 doses received (Card verified/verbal)** | |
| 3 doses                        | 1809 (57.6)    |
| 2 doses                        | 392 (12.5)     |
| 1 dose                         | 352 (11.2)     |
| 0 dose                         | 587 (18.7)     |

IQR= Interquartile Range, * defined as no. of persons/room, **data available for 3068 children, ***using WHO age-specific cutoffs

### Table S2 Study enrollment details

|                                | n       |
|--------------------------------|---------|
| Number of households approached | 4181    |
| Antibiotic class | Abbreviation | Sensitive (S) | Intermediate (I) | Resistant (R) |
|------------------|--------------|--------------|-----------------|--------------|
| Chloramphenicol (30 µg) | C | ≥ 21 | NA | ≤ 20 |
| Erythromycin (15 µg) | E | ≥ 21 | 16-20 | ≤ 15 |
| Penicillin: Oxacillin (1µg) | OX | ≥ 20 | NA | NA |
| Ofloxacin (5 µg) | OFX | ≥ 16 | 13-15 | ≤ 12 |
| Cotrimoxazole (25 µg) | SXT | ≥ 19 | 16-18 | ≤ 15 |
| Tetracycline (30 µg) | TE | ≥ 28 | 25-27 | ≤ 24 |
| Vancomycin (30 µg) | VA | ≥ 17 | NA | NA |

*Streptococcus pneumoniae* Minimal Inhibitory Concentration (MIC) (ug/ml)

| Antibiotic class | Abbreviation | ≤ 2 | 4 | ≥ 8 |
|------------------|--------------|-----|---|-----|
| Penicillin (non-meninitis) | P | ≤ 2 | 4 | ≥ 8 |
| Ceftriaxone (non-meninitis) | CRO | ≤ 1 | 2 | ≥ 4 |
| Vancomycin | VA | ≤ 1 | NA | NA |